itpa gene variants protect anaemia patients treated chronic hepatitis c 
chronic infection hepatitis c virus hcv affects million people worldwide important cause liver-related morbidity mortality standard care therapy combines pegylated interferon pegifn alpha ribavirin rbv associated range treatment-limiting adverse effects one important rbv-induced haemolytic anaemia affects patients severe enough require dose modification % patients show genetic variants leading inosine triphosphatase deficiency condition thought clinically important protect haemolytic anaemia hepatitis-c-infected patients receiving rbv 
